Answers are grounded in this paper and cite their sources.
Abstract 6-prenylnaringenin (6-PN) has recently attracted attention for its chemopreventive, cytotoxic, and analgesic activities; however, information on its pharmacokinetic properties remains limited, making it difficult to interpret its biological effects. This study thus investigated the metabolism of 6-PN in humans, mice, and rats, as well as its intestinal transport and interaction with ABCB1 in humans. 6-PN (10 µM) was efficiently metabolized predominantly via phase II conjugation across all studied species. Overall, 13 phase I/II metabolites were detected, including novel sulfoglucuronide diconjugates not previously reported for structurally similar hop prenylflavonoids. Importantly, murine hepatic metabolism of 6-PN more closely resembled its human hepatic biotransformation profile, favoring murine over rat models in pharmacokinetics studied. Further, 6-PN showed appreciable transport in the absorptive AB direction, while the observed BA-over-AB asymmetry was not reduced by ABCB1/ABCG2 inhibition, although it modulated ABCB1 substrate transport in a model- and substrate-dependent manner. Overall, these data indicate that 6-PN can undergo transepithelial transport in the absorptive direction, whereas extensive phase II metabolism may substantially shape its bioavailability.
No takes yet. Share an insight, caveat, or question.
Šadibolová et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: